4-Amino-1-(4-methylpiperazin-1-yl)butan-1-one | 938518-37-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-Amino-1-(4-methylpiperazin-1-yl)butan-1-one
• CAS: 938518-37-7
• 化学式: C₉H₁₉N₃O
• mdl: MFCD09726328
• 分子量: 185.269
• InChiKey: LNUULIUXDCLFOK-UHFFFAOYSA-N

物化性质

• 沸点：
  326.5±37.0 °C(Predicted)
• 密度：
  1.049±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  49.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,7-二氯喹啉 、 4-Amino-1-(4-methylpiperazin-1-yl)butan-1-one 以 苯酚 为溶剂， 以54%的产率得到4-(7-chloroquinolin-4-ylamino)-1-(4-methylpiperazin-1-yl)butan-1-one
  参考文献：
  名称：

  Antiplasmodial activity of new 4-aminoquinoline derivatives against chloroquine resistant strain

  摘要：

  Emergence and spread of multidrug resistant strains of Plasmodium falciparum has severely limited the antimalarial chemotherapeutic options. In order to overcome the obstacle, a set of new side-chain modified 4-aminoquinolines were synthesized and screened against chloroquine-sensitive (3D7) and chloroquine-resistant (K1) strains of P. falciparum. The key feature of the designed molecules is the use of methylpiperazine linked α, β(3)- and γ-amino acids to generate novel side chain modified 4-aminoquinoline analogues. Among the evaluated compounds, 20c and 30 were found more potent than CQ against K1 and displayed a four-fold and a three-fold higher activity respectively, with a good selectivity index (SI=5846 and 11,350). All synthesized compounds had resistance index between 1.06 and >14.13 as against 47.2 for chloroquine. Biophysical studies suggested that this series of compounds act on heme polymerization target.

  DOI：

  10.1016/j.bmc.2014.05.024
• 作为产物：
  描述：

  tert-butyl 4-(4-methylpiperazin-1-yl)-4-oxobutylcarbamate 在 盐酸 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-Amino-1-(4-methylpiperazin-1-yl)butan-1-one
  参考文献：
  名称：

  Antiplasmodial activity of new 4-aminoquinoline derivatives against chloroquine resistant strain

  摘要：

  Emergence and spread of multidrug resistant strains of Plasmodium falciparum has severely limited the antimalarial chemotherapeutic options. In order to overcome the obstacle, a set of new side-chain modified 4-aminoquinolines were synthesized and screened against chloroquine-sensitive (3D7) and chloroquine-resistant (K1) strains of P. falciparum. The key feature of the designed molecules is the use of methylpiperazine linked α, β(3)- and γ-amino acids to generate novel side chain modified 4-aminoquinoline analogues. Among the evaluated compounds, 20c and 30 were found more potent than CQ against K1 and displayed a four-fold and a three-fold higher activity respectively, with a good selectivity index (SI=5846 and 11,350). All synthesized compounds had resistance index between 1.06 and >14.13 as against 47.2 for chloroquine. Biophysical studies suggested that this series of compounds act on heme polymerization target.

  DOI：

  10.1016/j.bmc.2014.05.024

文献信息

• Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
  申请人：GENKYO TEX SA

  公开号：EP2166010A1

  公开（公告）日：2010-03-24

  The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式(I)的吡唑吡啶衍生物，其药物组成物以及它们用于治疗和/或预防与烟酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）相关的疾病或症状的用途。
• PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  申请人：Page Patrick

  公开号：US20110269757A1

  公开（公告）日：2011-11-03

  The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式（I）的吡唑吡啶衍生物，其制药组合物以及它们用于治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）有关的疾病或症状的用途。
• Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
  申请人：vTv Therapeutics LLC

  公开号：US10030011B2

  公开（公告）日：2018-07-24

  Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.

  本研究提供了取代的融合咪唑衍生物、其制备方法、包含取代的融合咪唑衍生物的药物组合物以及用于治疗炎症的方法。取代的融合咪唑衍生物可控制血红素加氧酶的活性或数量，或同时控制活性和数量。
• Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
  申请人：vTv Therapeutics LLC

  公开号：US10172840B2

  公开（公告）日：2019-01-08

  The disclosure provides pharmaceutical compositions comprising Bach1 Inhibitors and Nrf2 Activators. The disclosure also provides methods of treating diseases such as psoriasis, multiple sclerosis, and COPD comprising administering a Bach1 Inhibitor and a Nrf2 Activator to a subject in need thereof.

  本公开提供了包含 Bach1 抑制剂和 Nrf2 激活剂的药物组合物。本公开还提供了治疗牛皮癣、多发性硬化症和慢性阻塞性肺病等疾病的方法，包括向有需要的受试者施用 Bach1 抑制剂和 Nrf2 激活剂。
• Methods and compositions for treating cancer
  申请人：THE UNIVERSITY OF CHICAGO

  公开号：US10888569B1

  公开（公告）日：2021-01-12

  The disclosure relates to improved therapeutic methods for treating cancer patients. The methods include a method for treating cancer in a subject comprising administering an effective amount of a BACH1 inhibitor and an ETC inhibitor to the subject. Further aspects of the disclosure relate to a method for treating cancer in a subject comprising: administering a first therapeutic regimen comprising an ETC inhibitor to the subject after a biological sample from the subject was determined to have a decreased or substantially the same level of expression of BACH1 relative to a control sample or to a cut-off value; wherein the first therapeutic regimen excludes a BACH1 inhibitor; or administering a second therapeutic regimen comprising a BACH1 inhibitor and an ETC inhibitor to the subject after a biological sample from the subject was determined to have an increased level of expression of BACH1 relative to a control sample or a cut-off value.

  本公开涉及治疗癌症患者的改进治疗方法。这些方法包括治疗受试者癌症的方法，该方法包括向受试者施用有效量的 BACH1 抑制剂和 ETC 抑制剂。本公开的其他方面涉及一种治疗受试者癌症的方法，包括在确定受试者的生物样本相对于对照样本或临界值具有降低或基本相同的BACH1表达水平之后，向受试者施用包含ETC抑制剂的第一治疗方案；其中第一治疗方案不包括BACH1抑制剂；或 在确定受试者的生物样本相对于对照样本或临界值具有升高的BACH1表达水平之后，向受试者施用包含BACH1抑制剂和ETC抑制剂的第二治疗方案。